Complication | Evidence | PMID |
Cardiovascular | 1. In addition, several clinical studies have also shown that SGLT2 inhibitors could reduce blood pressure, body weight, serum uric acid levels and ameliorate cardiovascular risk in patients with diabetes. 2. RECENT FINDINGS: Several large CV outcome trials in patients with type 2 diabetes mellitus (T2DM) and with either established atherosclerotic CV disease (ASCVD) or at high risk for ASCVD reveal that SGLT2 inhibitors cause reductions in CV and HF endpoints. | 26228073 |
Atherosclerosis | 1. Inhibition of the sodium glucose co-transporter 2 (SGLT2) reduces cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) with atherosclerotic cardiovascular disease. | 30988077 |
Insulin resistance and inflammation | 1. We recently reported that the SGLT2 inhibitor empagliflozin increases fat utilization and browning in white adipose tissue and attenuates obesity-induced inflammation and insulin resistance by activating M2 macrophages. | 29376471 |